Do you want to read an article? Please log in or register.
Real-world Evidence on Clinical Outcomes of People with Type 1 Diabetes Using Open-Source and Commercial Automated Insulin Dosing Systems: A Systematic Review
Type 1 Diabetes
Related content
COMMENTED
Diabetes - General
Medicines for Treatment Intensification in Type 2 Diabetes and Type of Insulin in Type 1 and Type 2 Diabetes in Low-Resource Settings: Synopsis of the World Health Organization Guidelines on Second- and Third-Line Medicines and Type of Insulin for the Control of Blood Glucose Levels in Nonpregnant Adults With Diabetes Mellitus
Ann Intern Med.
Roglic G, Norris SL
doi: 10.7326/M18-1149.
Type 1 DiabetesType 2 DiabetesGlycemic Control
Clinical benefits of switching to insulin degludec irrespective of previous basal insulin therapy in people with Type 1 or Type 2 diabetes: evidence from a European, multicentre, retrospective, non-interventional study (EU-TREAT)
Diabet Med.
Knudsen ST, Lapolla A, Schultes B, Tentolouris N, Catarig AM, Wolden ML, Siegmund T
doi: 10.1111/dme.13976.
COMMENTED
Type 1 Diabetes
Glucose control using fast-acting insulin aspart in a real-world setting: a 1-year two-center study in people with type 1 diabetes using continuous glucose monitoring
★ 1
Recommended and commented by
Prof. emer. Dr Ulrich Keller, Faculty Member
Diabetes Obes Metab
Billion L, Charleer S, Verbraeken L, Sterckx M, Vangelabbeek K, De Block N, Janssen C, Van Dessel K, Dirinck E, Peiffer F, Bolsens N, Mathieu C, Gillard P, De Block C
doi: 10.1111/dom.14527
Type 1 Diabetes
A multicentre, UK, retrospective, observational study to assess the effectiveness of insulin glargine 300 units/ml in treating people with Type 1 diabetes mellitus in routine clinical practice (SPARTA)
Diabet Med.
Pang T, Bain SC, Black RNA, Boyle JG, Elliott J, Holcombe A, Lee KCS, Mulligan C, Saunders L, Yousseif A, Baxter M
doi: 10.1111/dme.13847.
Type 2 Diabetes
Insulin degludec/liraglutide (IDegLira) maintains glycaemic control and improves clinical outcomes, regardless of pre-trial insulin dose, in people with type 2 diabetes that is uncontrolled on basal insulin
Diabet Med.
Meneghini L, Doshi A, Gouet D, Vilsbøll T, Begtrup K, Őrsy P, Ranthe MF, Lingvay I
doi: 10.1111/dme.14178.
COMMENTED
Type 1 Diabetes
Impact of dietary protein on postprandial glycaemic control and insulin requirements in Type 1 diabetes: a systematic review
Diabet Med.
Paterson MA, King BR, Smart CEM, Smith T, Rafferty J, Lopez PE
doi: 10.1111/dme.14119.
COMMENTED
Type 1 Diabetes
Association of Insulin Dose, Cardiometabolic Risk Factors, and Cardiovascular Disease in Type 1 Diabetes During 30 Years of Follow-up in the DCCT/EDIC Study
Diabetes Care.
Braffett BH, Dagogo-Jack S, Bebu I, Sivitz WI, Larkin M, Kolterman O, Lachin JM, DCCT/EDIC Research Group
doi: 10.2337/dc18-1574.
COMMENTED
Diabetes - GeneralType 1 Diabetes
Effect of Oral Insulin on Prevention of Diabetes in Relatives of Patients With Type 1 Diabetes: A Randomized Clinical Trial
JAMA.
Writing Committee for the Type 1 Diabetes TrialNet Oral Insulin Study Group, Krischer JP, Schatz DA, Bundy B, Skyler JS, Greenbaum CJ
doi: 10.1001/
Type 1 Diabetes
Non-insulin treatments for Type 1 diabetes: critical appraisal of the available evidence and insight into future directions
Diabet Med.
Wright LA, Hirsch IB
doi: 10.1111/dme.13941.